CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,222 enrolled
Drug / intervention
Candesartan cilexetil / hydrochlorothiazidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02016183
NCT02016183N/ACompleted
CompareCT.gov

ECARD Combination Tablets LD&HD Special Drug Use Surveillance: Long-term Use (12 Months)

Takeda·observational·Posted Dec 19, 2013·Updated Nov 9, 2018

In Brief

An observational study evaluating Candesartan cilexetil / hydrochlorothiazide for Hypertension. Completed, enrolled 3,222 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of long-term use of candesartan cilexetil / hydrochlorothiazide combination tablets (ECARD) Combination Tablets LD\&HD in hypertensive patients in the routine clinical setting

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 19, 2013
Enrollment StartApr 1, 2009
Primary CompletionSep 30, 2012
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 12.5 years ago

Interventions

Candesartan cilexetil / hydrochlorothiazidedrug

Candesartan cilexetil / hydrochlorothiazide combination tablets